Live
- Big B on being honoured with Mangeshkar Award: ‘Abhaar aur mera param saubhagya’
- Fashion Entrepreneur Fund opens up for pre registrations
- ICEA shares blueprint for India to become a global leader in chip value chain
- Meera Deosthale describes marriage as a ‘beautiful union yet huge responsibility’
- 1 in 4 Indians came across political content that turned out to be deepfake: Report
- Summer diet tips for mom-to-be to stay hydrated and healthy
- Rajender Rao Congress candidate for Karimnagar
- How stress can affect you
- Empowering individuals with knowledge about disease
- Promoting entrepreneurship & support to technology startups
WHO prequalifies BE's Typhoid vaccine
WHO prequalifies BE’s Typhoid vaccine
- With this, city-based Biological E becomes one of two pre-qualified suppliers of Typhoid Conjugate Vaccine to the UN
- TCV is a single-dose injectable vaccine; It can be administered to children from six months of age to adults up to the age of 45
Hyderabad: Biological E. Limited (BE), a city-based vaccines and pharmaceutical company, on Friday announced that its Typhoid Conjugate Vaccine (TCV) has been pre-qualified by the World Health Organisation (WHO).
With this pre-qualification, BE has become one of two pre-qualified suppliers of TCV to the UN agencies.
BE's TCV is a single-dose injectable vaccine, which can be administered to children from six months of age to adults up to the age of 45 and it is formulated with Vi polysaccharide conjugated to a carrier protein (CRM197).
The Vi polysaccharide antigen used in BE's TCV is derived from C. freundii, which is a non-pathogenic source (BSL 1 organism), compared to virulent Salmonella Typhi used by other manufacturers, and the carrier protein used for conjugation is a non-toxic CRM197 protein locally developed by BE through in-house R&D effort, the company said.
Clinical studies conducted in India have shown that the safety and immunogenicity profiles of this vaccine are comparable with those of the other WHO pre-qualified TCV. BE offers this vaccine as single-dose and multi-dose vials for ease of administration.
The vaccine was developed in collaboration with the GSK Vaccines Institute for Global Health (GVGH), based in Siena, Italy, which first developed the vaccine strain and transferred the technology to BE in 2013. BE has further developed the vaccine, including manufacturing process optimization and scale up, pre-clinical studies and comprehensive clinical trials for Phase I, II/III in India. This vaccine is being manufactured in BE's GMP manufacturing facilities in Hyderabad.
"This is a remarkable accomplishment and a significant milestone in the journey of our vaccines. I am delighted that we have been able to produce a new WHO pre-qualified vaccine. We believe that every year this vaccine would save about 1.5 Lakh people worldwide," said Mahima Datla, Managing Director, Biological E. Limited. "GSK, through its R&D efforts at GVGH, is proud to have played an essential role in providing technologies to Biological E for their Typhoid Conjugate Vaccine (TCV)," said Francesco Berlanda-Scorza, GVGH Director.
